Publisher
Springer Science and Business Media LLC
Reference23 articles.
1. Benschop RJ, Collins EC, Darling RJ, et al. Development of a novel antibody to calcitonin gene-related peptide for the treatment of osteoarthritis-related pain. Osteoarthr Cartil. 2014;22(4):578–85.
2. Monteith D, Collins EC, Vandermeulen C, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the CGRP binding monoclonal antibody LY2951742 (galcanezumab) in healthy volunteers. Front Pharmacol. 2017;8:740.
3. Goldberg SW, Silberstein SD. Targeting CGRP: a new era for migraine treatment. CNS Drugs. 2015;29:443–52.
4. Eli Lilly and Company. Lilly’s Emgality™ (galcanezumab-gnlm) receives U.S. FDA approval for the preventive treatment of migraine in adults [media release]. 5 Oct 2018.
http://investor.lilly.com/
.
5. Eli Lilly and Company. EMGALITY (galcanezumab-gnlm) injection, for subcutaneous use: US prescribing information. 2018.
http://pi.lilly.com/
. Accessed 11 Oct 2018.
Cited by
40 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献